InspireMD develops and commercializes carotid stent systems built around its MicroNet stent platform for carotid artery disease and stroke prevention. News for NSPR centers on CGuard Prime and CGuard product commercialization, U.S. and international demand, FDA interactions, IDE approvals, pivotal studies for TCAR-related use, and product quality actions such as the CGuard Prime 135 cm delivery-system recall.
Company updates also cover quarterly financial results, hospital adoption and procedure experience, publications from C-GUARDIANS studies, investor conference participation, and capital-market communications tied to its Nasdaq-listed common stock.
InspireMD (NSPR) announced that its CGuard EPS stent system has received a positive reimbursement opinion from the French National Authority for Health (HAS), effective October 25, 2021. This milestone marks a crucial step towards the commercial launch of CGuard EPS, previously approved by CNEDIMTS for use in treating carotid artery disease. The stent aims to enhance treatment options, moving away from surgical methods. InspireMD's unique MicroNet technology is designed to improve patient outcomes.
InspireMD, developer of the CGuard™ Embolic Prevention System, reported a revenue increase of 231.6% in Q2 2021, totaling $1,038,000 compared to $313,000 in Q2 2020, driven by a recovery in procedural volumes. The gross profit rose to $262,000, with a gross margin of 25.2%. However, operating expenses increased by 59.2% to $3,702,000. The net loss for the quarter was $3,507,000 or $0.46 per share. The company initiated the “C-Guardians” IDE clinical trial, transferring its stock listing to Nasdaq to enhance investor access.
InspireMD (Nasdaq: NSPR) announced it will release its fiscal Q1 2021 financial results on August 10, 2021, before the market opens. A conference call will follow at 8:30 a.m. ET to discuss these results and corporate developments. Participants must pre-register to join, with options for telephonic or webcast access available. The company aims to establish its CGuard™ Embolic Prevention Stent System for treating carotid artery disease and ensure stroke prevention.
InspireMD (Nasdaq: NSPR) has initiated patient enrollment in the U.S. registration C-Guardian trial for its CGuard™ Embolic Prevention Stent System aimed at treating Carotid Artery Disease. The trial anticipates enrolling 315 patients, with the first successful cases completed at Ballad Health System under Dr. Chris Metzger's supervision. InspireMD aims to establish CGuard EPS as a leading stent device in the U.S. market, building on positive prior global outcomes and leveraging its MicroNet® technology for superior patient results.
InspireMD announced that CEO Marvin Slosman will present a corporate overview at the LD Micro Virtual Invitational Conference from June 8-10, 2021. The presentation is scheduled for June 9 at 11:30 AM ET on Track 3. Investors can register to watch the presentation here. The company aims to set its MicroNet® technology as the standard for carotid stenting, enhancing stroke-free outcomes. InspireMD's common stock trades on Nasdaq under the symbol NSPR.
InspireMD, Inc. has announced the approval for its warrants, previously traded on NYSE American, to be listed on the Nasdaq Capital Market. Trading under the new symbols NSPRW and NSPRZ is set to commence on June 8, 2021. The company focuses on developing the CGuard™ Embolic Prevention System to prevent strokes from carotid artery disease. InspireMD aims to set a new standard in carotid stenting with its proprietary MicroNet® technology.
InspireMD (Nasdaq-CM: NSPR) announces the commencement of its shares trading on The Nasdaq Capital Market as of May 21, 2021. The Company aims to enhance awareness, broaden its shareholder base, and improve trading liquidity to establish a standard of care in treating Carotid Artery Disease and stroke prevention. CEO Marvin Slosman emphasized the importance of this milestone in the Company's evolution. InspireMD utilizes its proprietary MicroNet technology to provide better outcomes in carotid stenting.
InspireMD, a developer of the CGuard™ Embolic Prevention System for stroke prevention in Carotid Artery Disease, will present at the Investor Summit Conference on May 17, 2021. Chief Executive Officer Marvin Slosman is scheduled to speak at 11:00am ET.
Investors are invited to request one-on-one meetings with Mr. Slosman post-conference. Registration for the event is available here.
InspireMD, a developer of stroke prevention technologies, has appointed Kathryn Arnold to its Board of Directors. With over 20 years in the medical device industry, Arnold's expertise in marketing and commercialization is expected to enhance InspireMD's strategic direction. Her previous experience includes leadership roles at Guidant and Kensey Nash. Arnold emphasized the need for effective solutions in carotid artery disease, noting the promising design of InspireMD's CGuard stent and its clinical performance data. InspireMD aims to establish its MicroNet technology as a standard in carotid stenting.
InspireMD, Inc. announced its successful up-listing to the Nasdaq Capital Market, effective May 21, 2021. The first quarter of 2021 showed a revenue decrease of 2.7%, totaling $1.006 million, with CGuard revenue remaining stable while MGuard Prime EPS revenue dropped by 41.3%. Gross profit fell by 64.1% to $106,000, and net loss increased to $3.243 million. The company raised $35.1 million through equity transactions. InspireMD is optimistic about the CGuard EPS's potential and plans for global expansion, especially in China.